Source / episode info

• **Episode:**152
• **Title:**Divine Intervention Episode 152 – Comprehensive USMLE Renal Pharmacology 4 (Final Part).
• **Published:**2019-09-13
• Source:Episode page

One-liner

This episode comprehensively reviews collecting duct physiology, detailing how aldosterone-mediated sodium reabsorption (via ENaC) drives potassium excretion (via ROMK), and covers the pharmacology of mineralocorticoid receptor antagonists, V2 receptor antagonists, and various diuretics used to manage electrolyte imbalances and diabetes insipidus.

High-yield summary

• Aldosterone Axis: Aldosterone activates the Epithelial Sodium Channel (ENaC) on the principal cell's apical membrane (urine side), creating a negative lumen potential that drives potassium excretion through the ROMK channel.
• Potassium Sparing Diuretics (e.g., Spironolactone, Eplerenone): These drugs block mineralocorticoid receptors, decreasing ENaC activity. This leads to decreased negative luminal charge, impairing K+ secretion and causing hyperkalemia. They also cause metabolic acidosis by inhibiting proton pumps in the -intercalated cells.
• V2 Receptor Antagonists (e.g., Tolvaptan): These drugs block ADH action at the V2 receptor, preventing water reabsorption in the collecting duct and treating SIADH or NDI.
• Diabetes Insipidus Management: Central DI is treated with Desmopressin (synthetic ADH). Nephrogenic DI (NDI) requires addressing the underlying cause; if non-lithium related, thiazides can be used.
• Lithium Toxicity Warning: Thiazide diuretics are absolutely contraindicated in lithium toxicity because they increase proximal sodium reabsorption, which enhances both sodium and lithium reabsorption, worsening toxicity.

Learning objectives

• Describe the role of aldosterone and its receptors on the principal cells of the collecting duct.
• Differentiate the clinical presentation and management strategies for Central vs. Nephrogenic Diabetes Insipidus.
• Predict the electrolyte imbalances associated with various classes of diuretics (e.g., K+-sparing, Thiazides).
• Understand the mechanism of action and side effects of V2 receptor antagonists (Vaptans).
• Recognize the critical contraindications when treating NDI in patients with lithium toxicity.

Board exam buzzwords